Additive effects of resveratrol and doxorubicin on bladder cancer cells.

Simple item page
dc.contributor.authorSoares, Luciana Bicalho Moreira
dc.contributor.authorLima, Ana Paula Braga
dc.contributor.authorMelo, André Sacramento
dc.contributor.authorAlmeida, Tamires Cunha
dc.contributor.authorTeixeira, Luiz Fernando de Medeiros
dc.contributor.authorSilva, Glenda Nicioli da
dc.date.accessioned2023-01-26T19:06:39Z
dc.date.available2023-01-26T19:06:39Z
dc.date.issued2022pt_BR
dc.description.abstractThe treatment of bladder cancer remains a challenge in clinical practice. Different chemotherapeutic protocols can be used; however, it is common to observe tumor recurrence and secondary effects that result in toxicity. Doxorubicin (DOX), one of the most effective anticancer agents used to treat bladder cancer, can cause chronic cardiotoxicity, limiting its use in clinical practice. Resveratrol (RES), a natural product with potential antitumor activity against bladder cancer, is associated with rapid metabolism and low bioavailability and needs to be combined with chemotherapeutic drugs to improve its use. Our study aimed to assess the therapeutic effect of a low concentration of DOX (2µM) in combination with RES (150, 200 and 250µM) on two bladder cancer cell lines. We investigated the mechanism of interaction between the drugs by performing cytotoxicity, clonogenic, oxidative stress, cell migration, cell morphology and nuclear division index (NDI) assays. Cytotoxicity evaluation revealed an additive interaction between RES and DOX for both cell lines. Additionally, the results of cell colony formation, oxidative stress, cell migration, cell morphology and NDI assays showed that a combination of DOX and RES was more effective than RES or DOX alone. In conclusion, a low concentration of DOX combined with RES could potentiate the antitumor effects of the drugs on bladder cancer cells, thus overcoming the secondary effects caused by DOX and the low bioavailability of resveratrol.pt_BR
dc.identifier.citationSOARES, L. B. M. et al. Additive effects of resveratrol and doxorubicin on bladder cancer cells. Anti-Cancer Drugs, v. 33, n. 1, p. e389–e397, 2022. Disponível em: <https://journals.lww.com/anti-cancerdrugs/Fulltext/2022/01000/Additive_effects_of_resveratrol_and_doxorubicin_on.54.aspx>. Acesso em: 11 out. 2022.pt_BR
dc.identifier.doihttps://doi.org/10.1097/CAD.0000000000001218pt_BR
dc.identifier.issn0959-4973
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/16053
dc.identifier.uri2https://journals.lww.com/anti-cancerdrugs/Fulltext/2022/01000/Additive_effects_of_resveratrol_and_doxorubicin_on.54.aspxpt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectCell deathpt_BR
dc.subjectReactive oxygen speciespt_BR
dc.titleAdditive effects of resveratrol and doxorubicin on bladder cancer cells.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_AdditiveEffectsResveratrol.pdf
Size:
1020.33 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos